NEO NEOGENOMICS INC
FY2025 10-K
NEOGENOMICS INC (NEO) filed its fiscal year 2025 10-K annual report with the SEC on Feb 17, 2026. This page provides AI-powered analysis of the filing, including business overview, management discussion, risk factors, and key financial metrics from XBRL data.
AI Filing AnalysisFY2025 10-K
Business Overview
- • Core business: oncology-focused diagnostic testing and consultative services, including molecular and precision cancer testing
- • Emphasis on growth in therapy selection and Molecular Residual Disease (MRD) testing with launches under a 2026 launch excellence program
Management Discussion & Analysis
- • Revenue $727.3M in 2025, up 10.1% YoY or $66.8M, driven by higher test volumes, higher value tests, reimbursement, and Pathline acquisition
- • Gross profit $314.3M, margin 43.2% in 2025 vs 43.9% in 2024, a 0.7% margin decline mainly from Pathline acquisition and rising costs
Risk Factors
- • FDA potential regulation of Laboratory Developed Tests requiring clinical trials and approvals, risking operational disruptions and costs
- • Global conflicts and political unrest posing business disruption risks with no specific regional revenue exposure disclosed
Get deeper insights on NEOGENOMICS INC
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.